This article was originally published in The Tan Sheet
Three-year study finding "vitamin E supplement intake above 450 IU per day may block early atherosclerotic progression" pointed to by CRN to dispute contrary research in recent Journal of the American Medical Association article. Conducted by James Dwyer, PhD, University of Southern California, et al., and presented at a recent AHA conference, the CRN-cited study hypothesizes that other research on vitamin E and coronary heart disease may have failed to detect benefits due to insufficient dosing and intervention at later disease stages. Conversely, Emma Meagher, MD, University of Pennsylvania, et al., failed "to detect any impact of vitamin E on three quantitative indices of lipid peroxidation" in the March 7 JAMA study. Pennsylvania group's conclusions "were based on short-term markers of a biochemical process, not clinically significant disease markers" such as "the build-up of plaque in the arteries," CRN maintains
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: